{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:20:55Z","timestamp":1790389255396,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    X-linked adrenoleukodystrophy (X-ALD) is a severe genetic disorder caused by\n                    <jats:italic>ABCD1<\/jats:italic>\n                    mutations, resulting in the buildup of very-long-chain fatty acids, leading to significant neurological decline and adrenal insufficiency. Despite advancements in understanding the mechanisms of X-ALD, its pathophysiology remains incompletely understood, complicating the development of effective treatments. This review provides a comprehensive overview of X-ALD, with a focus on the genetic and biochemical roles of\n                    <jats:italic>ABCD1<\/jats:italic>\n                    and the impacts of its mutations. Current therapeutic approaches are evaluated, discussing their limitations, and emphasizing the need to fully elucidate the pathogenesis of X-ALD. Additionally, this review highlights the importance of international collaboration to enhance systematic data collection and advance biomarker discovery, ultimately improving patient outcomes with X-ALD.\n                  <\/jats:p>","DOI":"10.1186\/s12944-024-02361-0","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T04:51:44Z","timestamp":1731300704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["From gene to therapy: a review of deciphering the role of ABCD1 in combating X-Linked adrenoleukodystrophy"],"prefix":"10.1186","volume":"23","author":[{"given":"Xinxin","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"2361_CR1","doi-asserted-by":"publisher","first-page":"107734","DOI":"10.1016\/j.ymgme.2023.107734","volume":"140","author":"C Videbaek","year":"2023","unstructured":"Videbaek C, Melgaard L, Lund AM, Gronborg SW. Newborn screening for adrenoleukodystrophy: International experiences and challenges. Mol Genet Metab. 2023;140:107734. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107734.","journal-title":"Mol Genet Metab"},{"key":"2361_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4331\/wjbc.v11.i3.99","volume":"11","author":"SV Palakuzhiyil","year":"2020","unstructured":"Palakuzhiyil SV, Christopher R, Chandra SR. Deciphering the modifiers for phenotypic variability of X-linked adrenoleukodystrophy. World J Biol Chem. 2020;11:99\u2013111. https:\/\/doi.org\/10.4331\/wjbc.v11.i3.99.","journal-title":"World J Biol Chem"},{"key":"2361_CR3","doi-asserted-by":"publisher","unstructured":"Engelen M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7. https:\/\/doi.org\/10.1186\/1750-1172-7-51.","DOI":"10.1186\/1750-1172-7-51"},{"key":"2361_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/brain\/awt361","volume":"137","author":"M Engelen","year":"2014","unstructured":"Engelen M, et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain. 2014;137:693\u2013706. https:\/\/doi.org\/10.1093\/brain\/awt361.","journal-title":"Brain"},{"key":"2361_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/jnen\/59.2.89","volume":"59","author":"JM Powers","year":"2000","unstructured":"Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol. 2000;59:89\u2013102. https:\/\/doi.org\/10.1093\/jnen\/59.2.89.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2361_CR6","doi-asserted-by":"publisher","first-page":"1309053","DOI":"10.3389\/fendo.2023.1309053","volume":"14","author":"M Cappa","year":"2023","unstructured":"Cappa M, Todisco T, Bizzarri C. X-linked adrenoleukodystrophy and primary adrenal insufficiency. Front Endocrinol (Lausanne). 2023;14:1309053. https:\/\/doi.org\/10.3389\/fendo.2023.1309053.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2361_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s1096-7192(03)00098-2","volume":"79","author":"F Valianpour","year":"2003","unstructured":"Valianpour F, et al. Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry. Mol Genet Metab. 2003;79:189\u201396. https:\/\/doi.org\/10.1016\/s1096-7192(03)00098-2.","journal-title":"Mol Genet Metab"},{"key":"2361_CR8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1248\/bpb.b18-00723","volume":"42","author":"T Imanaka","year":"2019","unstructured":"Imanaka T. Biogenesis and function of Peroxisomes in Human Disease with a focus on the ABC transporter. Biol Pharm Bull. 2019;42:649\u201365. https:\/\/doi.org\/10.1248\/bpb.b18-00723.","journal-title":"Biol Pharm Bull"},{"key":"2361_CR9","doi-asserted-by":"publisher","unstructured":"Tawbeh A, Gondcaille C, Trompier D, Savary S. Peroxisomal ABC transporters: an update. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22116093.","DOI":"10.3390\/ijms22116093"},{"key":"2361_CR10","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s11011-015-9701-1","volume":"30","author":"M Morita","year":"2015","unstructured":"Morita M, et al. Brain microsomal fatty acid elongation is increased in abcd1-deficient mouse during active myelination phase. Metab Brain Dis. 2015;30:1359\u201367. https:\/\/doi.org\/10.1007\/s11011-015-9701-1.","journal-title":"Metab Brain Dis"},{"key":"2361_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.biochi.2013.09.009","volume":"98","author":"D Trompier","year":"2014","unstructured":"Trompier D, et al. Brain Peroxisomes Biochimie. 2014;98:102\u201310. https:\/\/doi.org\/10.1016\/j.biochi.2013.09.009.","journal-title":"Brain Peroxisomes Biochimie"},{"key":"2361_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40478-023-01595-w","volume":"11","author":"K Martinovic","year":"2023","unstructured":"Martinovic K, Bauer J, Kunze M, Berger J, Forss-Petter S. Abcd1 deficiency accelerates cuprizone-induced oligodendrocyte loss and axonopathy in a demyelinating mouse model of X-linked adrenoleukodystrophy. Acta Neuropathol Commun. 2023;11:98. https:\/\/doi.org\/10.1186\/s40478-023-01595-w.","journal-title":"Acta Neuropathol Commun"},{"key":"2361_CR13","doi-asserted-by":"publisher","first-page":"E211","DOI":"10.1152\/ajpendo.90736.2008","volume":"296","author":"S Fourcade","year":"2009","unstructured":"Fourcade S, et al. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab. 2009;296:E211\u2013221. https:\/\/doi.org\/10.1152\/ajpendo.90736.2008.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2361_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1248\/cpb.c21-01021","volume":"70","author":"K Kawaguchi","year":"2022","unstructured":"Kawaguchi K, Imanaka T. Substrate specificity and the Direction of Transport in the ABC transporters ABCD1-3 and ABCD4. Chem Pharm Bull (Tokyo). 2022;70:533\u20139. https:\/\/doi.org\/10.1248\/cpb.c21-01021.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2361_CR15","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1248\/bpb.b12-00411","volume":"35","author":"M Morita","year":"2012","unstructured":"Morita M, Shinbo S, Asahi A, Imanaka T. Very long chain fatty acid beta-oxidation in astrocytes: contribution of the ABCD1-dependent and -independent pathways. Biol Pharm Bull. 2012;35:1972\u20139. https:\/\/doi.org\/10.1248\/bpb.b12-00411.","journal-title":"Biol Pharm Bull"},{"key":"2361_CR16","doi-asserted-by":"publisher","first-page":"100654","DOI":"10.1016\/j.jbc.2021.100654","volume":"296","author":"K Kitai","year":"2021","unstructured":"Kitai K, et al. The lysosomal protein ABCD4 can transport vitamin B(12) across liposomal membranes in vitro. J Biol Chem. 2021;296:100654. https:\/\/doi.org\/10.1016\/j.jbc.2021.100654.","journal-title":"J Biol Chem"},{"key":"2361_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/361726a0","volume":"361","author":"J Mosser","year":"1993","unstructured":"Mosser J, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature. 1993;361:726\u201330. https:\/\/doi.org\/10.1038\/361726a0.","journal-title":"Nature"},{"key":"2361_CR18","doi-asserted-by":"publisher","first-page":"34492","DOI":"10.1074\/jbc.M607183200","volume":"281","author":"MP Pinto","year":"2006","unstructured":"Pinto MP, et al. The import competence of a peroxisomal membrane protein is determined by Pex19p before the docking step. J Biol Chem. 2006;281:34492\u2013502. https:\/\/doi.org\/10.1074\/jbc.M607183200.","journal-title":"J Biol Chem"},{"key":"2361_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/humu.1227","volume":"18","author":"S Kemp","year":"2001","unstructured":"Kemp S, et al. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat. 2001;18:499\u2013515. https:\/\/doi.org\/10.1002\/humu.1227.","journal-title":"Hum Mutat"},{"key":"2361_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TACG.S49590","volume":"8","author":"C Wiesinger","year":"2015","unstructured":"Wiesinger C, Eichler FS, Berger J. The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis. Appl Clin Genet. 2015;8:109\u201321. https:\/\/doi.org\/10.2147\/TACG.S49590.","journal-title":"Appl Clin Genet"},{"key":"2361_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1023\/a:1022535930009","volume":"24","author":"KD Smith","year":"1999","unstructured":"Smith KD, et al. X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem Res. 1999;24:521\u201335. https:\/\/doi.org\/10.1023\/a:1022535930009.","journal-title":"Neurochem Res"},{"key":"2361_CR22","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1212\/wnl.57.11.1956","volume":"57","author":"GN O\u2019Neill","year":"2001","unstructured":"O\u2019Neill GN, Aoki M, Brown RH. Jr. ABCD1 translation-initiator mutation demonstrates genotype-phenotype correlation for AMN. Neurology. 2001;57:1956\u201362. https:\/\/doi.org\/10.1212\/wnl.57.11.1956.","journal-title":"Neurology"},{"key":"2361_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ana.410400221","volume":"40","author":"GC Korenke","year":"1996","unstructured":"Korenke GC, et al. Cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype. Ann Neurol. 1996;40:254\u20137. https:\/\/doi.org\/10.1002\/ana.410400221.","journal-title":"Ann Neurol"},{"key":"2361_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s10038-020-00866-x","volume":"66","author":"Y Shibata","year":"2021","unstructured":"Shibata Y, et al. Adrenoleukodystrophy siblings with a novel ABCD1 missense variant presenting with phenotypic differences: a case report and literature review. J Hum Genet. 2021;66:535\u20137. https:\/\/doi.org\/10.1038\/s10038-020-00866-x.","journal-title":"J Hum Genet"},{"key":"2361_CR25","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1212\/wnl.34.11.1410","volume":"34","author":"HW Moser","year":"1984","unstructured":"Moser HW, et al. Bone marrow transplant in adrenoleukodystrophy. Neurology. 1984;34:1410\u20137. https:\/\/doi.org\/10.1212\/wnl.34.11.1410.","journal-title":"Neurology"},{"key":"2361_CR26","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJM199006283222607","volume":"322","author":"P Aubourg","year":"1990","unstructured":"Aubourg P, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med. 1990;322:1860\u20136. https:\/\/doi.org\/10.1056\/NEJM199006283222607.","journal-title":"N Engl J Med"},{"key":"2361_CR27","first-page":"1761","volume":"15","author":"DJ Loes","year":"1994","unstructured":"Loes DJ, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol. 1994;15:1761\u20136.","journal-title":"AJNR Am J Neuroradiol"},{"key":"2361_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S1474-4422(07)70177-1","volume":"6","author":"A Mahmood","year":"2007","unstructured":"Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol. 2007;6:687\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(07)70177-1.","journal-title":"Lancet Neurol"},{"key":"2361_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1742-2094-8-144","volume":"8","author":"PJ Orchard","year":"2011","unstructured":"Orchard PJ, et al. Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy. J Neuroinflammation. 2011;8:144. https:\/\/doi.org\/10.1186\/1742-2094-8-144.","journal-title":"J Neuroinflammation"},{"key":"2361_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10354-016-0534-2","volume":"167","author":"BR Turk","year":"2017","unstructured":"Turk BR, Moser AB, Fatemi A. Therapeutic strategies in adrenoleukodystrophy. Wien Med Wochenschr. 2017;167:219\u201326. https:\/\/doi.org\/10.1007\/s10354-016-0534-2.","journal-title":"Wien Med Wochenschr"},{"key":"2361_CR31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.1171242","volume":"326","author":"N Cartier","year":"2009","unstructured":"Cartier N, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326:818\u201323. https:\/\/doi.org\/10.1126\/science.1171242.","journal-title":"Science"},{"key":"2361_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/B978-0-12-386509-0.00010-7","volume":"507","author":"N Cartier","year":"2012","unstructured":"Cartier N, et al. Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy. Methods Enzymol. 2012;507:187\u201398. https:\/\/doi.org\/10.1016\/B978-0-12-386509-0.00010-7.","journal-title":"Methods Enzymol"},{"key":"2361_CR33","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1089\/hum.2021.053","volume":"32","author":"P Bougneres","year":"2021","unstructured":"Bougneres P, et al. Long-term Follow-Up of hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. Hum Gene Ther. 2021;32:1260\u20139. https:\/\/doi.org\/10.1089\/hum.2021.053.","journal-title":"Hum Gene Ther"},{"key":"2361_CR34","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","volume":"377","author":"F Eichler","year":"2017","unstructured":"Eichler F, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377:1630\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1700554.","journal-title":"N Engl J Med"},{"key":"2361_CR35","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/mt.2015.6","volume":"23","author":"Y Gong","year":"2015","unstructured":"Gong Y, et al. Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Mol Ther. 2015;23:824\u201334. https:\/\/doi.org\/10.1038\/mt.2015.6.","journal-title":"Mol Ther"},{"key":"2361_CR36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1089\/hum.2018.079","volume":"30","author":"Y Gong","year":"2019","unstructured":"Gong Y, et al. Intrathecal Adeno-Associated viral vector-mediated gene delivery for Adrenomyeloneuropathy. Hum Gene Ther. 2019;30:544\u201355. https:\/\/doi.org\/10.1089\/hum.2018.079.","journal-title":"Hum Gene Ther"},{"key":"2361_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41434-022-00355-0","volume":"30","author":"J Gong","year":"2023","unstructured":"Gong J, et al. Intracerebral lentiviral ABCD1 gene therapy in an early disease onset ALD mouse model. Gene Ther. 2023;30:18\u201330. https:\/\/doi.org\/10.1038\/s41434-022-00355-0.","journal-title":"Gene Ther"},{"key":"2361_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymthe.2021.05.022","volume":"30","author":"SA Hong","year":"2022","unstructured":"Hong SA, et al. In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment. Mol Ther. 2022;30:119\u201329. https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.022.","journal-title":"Mol Ther"},{"key":"2361_CR39","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.ymthe.2024.05.027","volume":"32","author":"R Gopalappa","year":"2024","unstructured":"Gopalappa R, et al. In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model. Mol Ther. 2024;32:2190\u2013206. https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.027.","journal-title":"Mol Ther"},{"key":"2361_CR40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jpeds.2004.10.067","volume":"146","author":"P Dubey","year":"2005","unstructured":"Dubey P, et al. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr. 2005;146:528\u201332. https:\/\/doi.org\/10.1016\/j.jpeds.2004.10.067.","journal-title":"J Pediatr"},{"key":"2361_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ecl.2016.01.003","volume":"45","author":"E Burtman","year":"2016","unstructured":"Burtman E, Regelmann MO. Endocrine dysfunction in X-Linked adrenoleukodystrophy. Endocrinol Metab Clin North Am. 2016;45:295\u2013309. https:\/\/doi.org\/10.1016\/j.ecl.2016.01.003.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2361_CR42","doi-asserted-by":"publisher","unstructured":"Kachwala I, Regelmann MO. Monitoring for and management of endocrine dysfunction in Adrenoleukodystrophy. Int J Neonatal Screen. 2022;8. https:\/\/doi.org\/10.3390\/ijns8010018.","DOI":"10.3390\/ijns8010018"},{"key":"2361_CR43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/j157v06n03_07","volume":"6","author":"MA Al-Omar","year":"2006","unstructured":"Al-Omar MA. The X-linked adrenoleukodystrophy (X-ALD) and oxidative stress. J Herb Pharmacother. 2006;6:125\u201334. https:\/\/doi.org\/10.1080\/j157v06n03_07.","journal-title":"J Herb Pharmacother"},{"key":"2361_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/TACG.S359479","volume":"15","author":"AM Volmrich","year":"2022","unstructured":"Volmrich AM, Cuenant LM, Forghani I, Hsieh SL, Shapiro LT. ABCD1 gene mutations: mechanisms and management of Adrenomyeloneuropathy. Appl Clin Genet. 2022;15:111\u201323. https:\/\/doi.org\/10.2147\/TACG.S359479.","journal-title":"Appl Clin Genet"},{"key":"2361_CR45","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/jnnp.67.3.290","volume":"67","author":"BM van Geel","year":"1999","unstructured":"van Geel BM, et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with Lorenzo\u2019s oil. J Neurol Neurosurg Psychiatry. 1999;67:290\u20139. https:\/\/doi.org\/10.1136\/jnnp.67.3.290.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2361_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jdn.10003","volume":"80","author":"BR Turk","year":"2020","unstructured":"Turk BR, Theda C, Fatemi A, Moser AB. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020;80:52\u201372. https:\/\/doi.org\/10.1002\/jdn.10003.","journal-title":"Int J Dev Neurosci"},{"key":"2361_CR47","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/hmg\/ddn085","volume":"17","author":"S Fourcade","year":"2008","unstructured":"Fourcade S, et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet. 2008;17:1762\u201373. https:\/\/doi.org\/10.1093\/hmg\/ddn085.","journal-title":"Hum Mol Genet"},{"key":"2361_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ana.22363","volume":"70","author":"J Lopez-Erauskin","year":"2011","unstructured":"Lopez-Erauskin J, et al. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann Neurol. 2011;70:84\u201392. https:\/\/doi.org\/10.1002\/ana.22363.","journal-title":"Ann Neurol"},{"key":"2361_CR49","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s13311-019-00735-2","volume":"16","author":"C Casasnovas","year":"2019","unstructured":"Casasnovas C, et al. Biomarker identification, Safety, and efficacy of high-dose antioxidants for Adrenomyeloneuropathy: a phase II pilot study. Neurotherapeutics. 2019;16:1167\u201382. https:\/\/doi.org\/10.1007\/s13311-019-00735-2.","journal-title":"Neurotherapeutics"},{"key":"2361_CR50","doi-asserted-by":"publisher","unstructured":"Ranea-Robles P, et al. Aberrant regulation of the GSK-3beta\/NRF2 axis unveils a novel therapy for adrenoleukodystrophy. EMBO Mol Med. 2018;10. https:\/\/doi.org\/10.15252\/emmm.201708604.","DOI":"10.15252\/emmm.201708604"},{"key":"2361_CR51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/bpa.12869","volume":"30","author":"S Fourcade","year":"2020","unstructured":"Fourcade S, et al. High-dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy. Brain Pathol. 2020;30:945\u201363. https:\/\/doi.org\/10.1111\/bpa.12869.","journal-title":"Brain Pathol"},{"key":"2361_CR52","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40291-021-00555-1","volume":"25","author":"SJ Keam","year":"2021","unstructured":"Keam SJ. Elivaldogene Autotemcel: first approval. Mol Diagn Ther. 2021;25:803\u20139. https:\/\/doi.org\/10.1007\/s40291-021-00555-1.","journal-title":"Mol Diagn Ther"},{"key":"2361_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11940-019-0605-y","volume":"21","author":"EJ Mallack","year":"2019","unstructured":"Mallack EJ, Turk B, Yan H, Eichler FS. The Landscape of hematopoietic stem cell transplant and gene therapy for X-Linked adrenoleukodystrophy. Curr Treat Options Neurol. 2019;21:61. https:\/\/doi.org\/10.1007\/s11940-019-0605-y.","journal-title":"Curr Treat Options Neurol"},{"key":"2361_CR54","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.biochi.2013.11.023","volume":"98","author":"J Berger","year":"2014","unstructured":"Berger J, Forss-Petter S, Eichler FS. Pathophysiology of X-linked adrenoleukodystrophy. Biochimie. 2014;98:135\u201342. https:\/\/doi.org\/10.1016\/j.biochi.2013.11.023.","journal-title":"Biochimie"},{"key":"2361_CR55","doi-asserted-by":"publisher","first-page":"1345503","DOI":"10.3389\/fneur.2024.1345503","volume":"15","author":"T Siwek","year":"2024","unstructured":"Siwek T, et al. Intrathecal administration of mesenchymal stem cells in patients with adrenomyeloneuropathy. Front Neurol. 2024;15:1345503. https:\/\/doi.org\/10.3389\/fneur.2024.1345503.","journal-title":"Front Neurol"},{"key":"2361_CR56","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","volume":"22","author":"AO Gupta","year":"2022","unstructured":"Gupta AO, et al. Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy. Expert Opin Biol Ther. 2022;22:1151\u201362. https:\/\/doi.org\/10.1080\/14712598.2022.2124857.","journal-title":"Expert Opin Biol Ther"},{"key":"2361_CR57","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41467-023-37262-w","volume":"14","author":"A Lauer","year":"2023","unstructured":"Lauer A, et al. Hematopoietic stem-cell gene therapy is associated with restored white matter microvascular function in cerebral adrenoleukodystrophy. Nat Commun. 2023;14:1900. https:\/\/doi.org\/10.1038\/s41467-023-37262-w.","journal-title":"Nat Commun"},{"key":"2361_CR58","doi-asserted-by":"publisher","unstructured":"Raas Q, et al. Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy. J Clin Invest. 2021;131. https:\/\/doi.org\/10.1172\/JCI142500.","DOI":"10.1172\/JCI142500"},{"key":"2361_CR59","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.1038\/s41598-019-44140-3","volume":"9","author":"PJ Orchard","year":"2019","unstructured":"Orchard PJ, et al. Association between APOE4 and biomarkers in cerebral adrenoleukodystrophy. Sci Rep. 2019;9:7858. https:\/\/doi.org\/10.1038\/s41598-019-44140-3.","journal-title":"Sci Rep"},{"key":"2361_CR60","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/j.1476-5381.2011.01435.x","volume":"164","author":"S Kemp","year":"2011","unstructured":"Kemp S, Theodoulou FL, Wanders RJ. Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance. Br J Pharmacol. 2011;164:1753\u201366. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01435.x.","journal-title":"Br J Pharmacol"},{"key":"2361_CR61","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1093\/hmg\/9.18.2609","volume":"9","author":"G Unterrainer","year":"2000","unstructured":"Unterrainer G, Molzer B, Forss-Petter S, Berger J. Co-expression of mutated and normal adrenoleukodystrophy protein reduces protein function: implications for gene therapy of X-linked adrenoleukodystrophy. Hum Mol Genet. 2000;9:2609\u201316. https:\/\/doi.org\/10.1093\/hmg\/9.18.2609.","journal-title":"Hum Mol Genet"},{"key":"2361_CR62","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s13311-022-01311-x","volume":"20","author":"CL Nemeth","year":"2023","unstructured":"Nemeth CL, et al. Targeted brain delivery of Dendrimer-4-Phenylbutyrate ameliorates neurological deficits in a long-term ABCD1-Deficient mouse model of X-Linked adrenoleukodystrophy. Neurotherapeutics. 2023;20:272\u201383. https:\/\/doi.org\/10.1007\/s13311-022-01311-x.","journal-title":"Neurotherapeutics"},{"key":"2361_CR63","doi-asserted-by":"publisher","first-page":"112214","DOI":"10.1016\/j.biopha.2021.112214","volume":"143","author":"CY Ma","year":"2021","unstructured":"Ma CY, et al. Management of adrenoleukodystrophy: from pre-clinical studies to the development of new therapies. Biomed Pharmacother. 2021;143:112214. https:\/\/doi.org\/10.1016\/j.biopha.2021.112214.","journal-title":"Biomed Pharmacother"},{"key":"2361_CR64","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1093\/hmg\/ddx249","volume":"26","author":"LR Strachan","year":"2017","unstructured":"Strachan LR, et al. A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination. Hum Mol Genet. 2017;26:3600\u201314. https:\/\/doi.org\/10.1093\/hmg\/ddx249.","journal-title":"Hum Mol Genet"},{"key":"2361_CR65","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ymgme.2006.05.001","volume":"89","author":"WC Hubbard","year":"2006","unstructured":"Hubbard WC, et al. Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings. Mol Genet Metab. 2006;89:185\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2006.05.001.","journal-title":"Mol Genet Metab"},{"key":"2361_CR66","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ymgme.2015.02.002","volume":"114","author":"BH Vogel","year":"2015","unstructured":"Vogel BH, et al. Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines. Mol Genet Metab. 2015;114:599\u2013603. https:\/\/doi.org\/10.1016\/j.ymgme.2015.02.002.","journal-title":"Mol Genet Metab"},{"key":"2361_CR67","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/gim.2016.68","volume":"19","author":"AR Kemper","year":"2017","unstructured":"Kemper AR, et al. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genet Med. 2017;19:121\u20136. https:\/\/doi.org\/10.1038\/gim.2016.68.","journal-title":"Genet Med"},{"key":"2361_CR68","doi-asserted-by":"publisher","unstructured":"Mallack EJ, Gao K, Engelen M, Kemp S. Structure and Function of the ABCD1 Variant Database: 20 Years, 940 Pathogenic Variants, and 3400 Cases of Adrenoleukodystrophy. Cells 11, https:\/\/doi.org\/10.3390\/cells11020283 (2022).","DOI":"10.3390\/cells11020283"},{"key":"2361_CR69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s43856-024-00605-9","volume":"4","author":"YRJ Jaspers","year":"2024","unstructured":"Jaspers YRJ, et al. Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy. Commun Med (Lond). 2024;4:175. https:\/\/doi.org\/10.1038\/s43856-024-00605-9.","journal-title":"Commun Med (Lond)"},{"key":"2361_CR70","doi-asserted-by":"publisher","unstructured":"Honey MIJ, Jaspers YRJ, Engelen M, Kemp S, Huffnagel IC. Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need. Cells 10, https:\/\/doi.org\/10.3390\/cells10123427 (2021).","DOI":"10.3390\/cells10123427"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02361-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T21:06:52Z","timestamp":1731445612000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02361-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02361-0","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}